GRCE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
GRCE is not a good buy right now for a Beginner long-term investor with $50,000-$100,000 available. The stock has a meaningful fundamental overhang from the FDA CRL and is still in a recovery/approval-resolution phase rather than a clear long-term uptrend. While the pre-market price is near support and options sentiment is bullish, the technical setup is mixed and the analyst target cuts show reduced near-term upside. For an impatient investor, this is not a strong immediate buy.
GRCE is trading pre-market at 2.37, slightly above pivot support at 2.301 and below first resistance at 2.437. Momentum is improving with a positive and expanding MACD histogram (0.032), but RSI_6 at 57.02 is only neutral. The larger trend remains bearish because SMA_200 > SMA_20 > SMA_5, indicating the stock is still below a healthy long-term trend structure. Near-term price behavior suggests limited upside unless it clears 2.437 and then 2.52 with follow-through.
["The Phase 3 STRIVE-ON study met its primary endpoint, showing a 19% reduction in hypotension with IV nimodipine.", "FY 2026 net loss improved to $7.8 million from the prior year.", "R&D expenses fell sharply to $2.4 million from $9.5 million as the Phase 3 trial wrapped up, improving cash efficiency.", "Analyst firms still maintain Buy ratings, and management is expected to pursue a Type A meeting to clarify resubmission timelines."]
["FDA issued a complete response letter in April 2026 for GTx-104, citing CMC deficiencies and some non-clinical concerns.", "Craig-Hallum and TD Cowen both cut price targets sharply, signaling lowered near-term expectations.", "Shares are expected to lack meaningful upside until greater regulatory visibility emerges.", "No strong insider buying, hedge fund accumulation, or recent congress trading support is present."]
Latest quarter/annual financial data is limited, but the most recent FY 2026 results show a net loss of $7.8 million, improved from the prior year. The company also reduced R&D expense to $2.4 million from $9.5 million because the Phase 3 STRIVE-ON trial for GT-104 was completed. That suggests improved operating efficiency, but it is not yet evidence of durable revenue growth, since the company remains development-stage and still depends on regulatory progress.
Recent analyst activity is still constructive on rating, with both Craig-Hallum and TD Cowen keeping Buy ratings. However, both firms sharply lowered price targets: Craig-Hallum to $4 from $11 and TD Cowen to $8 from $12. This shows analysts remain positive on the company’s longer-term potential but are clearly less optimistic on timing and near-term upside. Wall Street’s pro view is that the FDA issues appear regulatory/CMC-related rather than clinical, so resubmission may eventually unlock value. The con view is that the CRL delays commercialization and the stock likely needs more visibility before rerating higher.
